1. Home
  2. SPGI vs VRTX Comparison

SPGI vs VRTX Comparison

Compare SPGI & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPGI
  • VRTX
  • Stock Information
  • Founded
  • SPGI 1860
  • VRTX 1989
  • Country
  • SPGI United States
  • VRTX United States
  • Employees
  • SPGI N/A
  • VRTX N/A
  • Industry
  • SPGI Finance: Consumer Services
  • VRTX EDP Services
  • Sector
  • SPGI Finance
  • VRTX Technology
  • Exchange
  • SPGI Nasdaq
  • VRTX Nasdaq
  • Market Cap
  • SPGI 150.8B
  • VRTX 128.5B
  • IPO Year
  • SPGI N/A
  • VRTX 1991
  • Fundamental
  • Price
  • SPGI $503.39
  • VRTX $451.23
  • Analyst Decision
  • SPGI Buy
  • VRTX Buy
  • Analyst Count
  • SPGI 14
  • VRTX 29
  • Target Price
  • SPGI $581.25
  • VRTX $513.58
  • AVG Volume (30 Days)
  • SPGI 1.3M
  • VRTX 1.3M
  • Earning Date
  • SPGI 10-24-2024
  • VRTX 11-04-2024
  • Dividend Yield
  • SPGI 0.72%
  • VRTX N/A
  • EPS Growth
  • SPGI 46.60
  • VRTX N/A
  • EPS
  • SPGI 11.32
  • VRTX N/A
  • Revenue
  • SPGI $13,768,000,000.00
  • VRTX $10,625,800,000.00
  • Revenue This Year
  • SPGI $14.61
  • VRTX $12.20
  • Revenue Next Year
  • SPGI $6.37
  • VRTX $8.31
  • P/E Ratio
  • SPGI $44.48
  • VRTX N/A
  • Revenue Growth
  • SPGI 12.10
  • VRTX 10.06
  • 52 Week Low
  • SPGI $407.69
  • VRTX $346.29
  • 52 Week High
  • SPGI $533.29
  • VRTX $519.88
  • Technical
  • Relative Strength Index (RSI)
  • SPGI 50.42
  • VRTX 38.05
  • Support Level
  • SPGI $499.15
  • VRTX $489.02
  • Resistance Level
  • SPGI $515.80
  • VRTX $519.88
  • Average True Range (ATR)
  • SPGI 8.71
  • VRTX 15.39
  • MACD
  • SPGI 1.53
  • VRTX -5.21
  • Stochastic Oscillator
  • SPGI 67.77
  • VRTX 7.85

About SPGI S&P Global Inc.

S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: